(RTTNews) - BioArctic AB's partner Eisai Co., Ltd. (4523.T) presented long-term data from the Phase 3 Clarity AD trial showing that continuous treatment with LEQEMBI (lecanemab-irmb) provided sustained benefits in patients with early Alzheimer's disease.
Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.
